BMS gains second first-in-class approval of 2022 with Camzyos mavacamten

FDA’s approval of Camzyos mavacamten from BMS brings hypertrophic cardiomyopathy patients the first drug addressing the underlying cause of disease, and advances the pharma’s first-in-class strategy while marking an important step toward recouping the $13 billion spent to acquire it.

“Mavacamten is truly a transformational step in the right direction,” Samit Hirawat, CMO of Bristol Myers Squibb Co. (NYSE:BMY), told BioCentury. Most patients are taking beta blockers or calcium channel blockers, with some receiving antiarrhythmic medication disopyramide. None of those therapies directly intervene in the disease biology and come with significant side effects, Hirawat said...